Top

Published in:

Open Access 01-12-2009 | Case report

Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy

Authors: Shohrat Annaberdyev, Joseph Gibbons, Jeffrey M Hardacre

Published in: World Journal of Surgical Oncology | Issue 1/2009

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec^®; Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic and adjuvant settings. We report the case of a 61-year old man who was treated with neoadjuvant imatinib for a massive gastric GIST with the hope of avoiding a potential multi-visceral resection.

Available only for authorised users

Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007, 14: 14-24. 10.1245/s10434-006-9034-8.CrossRefPubMed

Demetri GD, von Mehren M, Blanke CD, Abbeele Van den AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347: 472-80. 10.1056/NEJMoa020461.CrossRefPubMed

Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M: CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998, 11: 728-734.PubMed

Andersson J, Sjogren H, Meis-Kindblom JM, Stenman G, Aman P, Kindblom LG: The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol. 2002, 160: 15-22.PubMedCentralCrossRefPubMed

Savage DG, Antman KH: Imatinib mesylate – a new oral targeted therapy. N Eng J Med. 2002, 346: 683-693. 10.1056/NEJMra013339.CrossRef

Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Eng J Med. 2001, 344: 1052-1056. 10.1056/NEJM200104053441404.CrossRef

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R: Approval Summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002, 8: 3034-3038.PubMed

Grochi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S, Casali PG: Surgery of residual disease following molecular-targeted therapy with Imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007, 245: 341-346. 10.1097/01.sla.0000242710.36384.1b.CrossRef

DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR: Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007, 245: 347-352. 10.1097/01.sla.0000236630.93587.59.PubMedCentralCrossRefPubMed

10.

Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt A, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet. 2004, 364: 1127-1134. 10.1016/S0140-6736(04)17098-0.CrossRefPubMed

11.

Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PCW, Brown M, Bertulli R, Judson IR: Initial and late resistance to Imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatments of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study. J Clin Oncol. 2005, 23: 5795-5804. 10.1200/JCO.2005.11.601.CrossRefPubMed

Title: Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
Authors: Shohrat Annaberdyev
Joseph Gibbons
Jeffrey M Hardacre
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2009
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-7-30

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Ruptured gallbladder as the first presentation of breast cancer

Comparison of intraoperative frozen section analysis for sentinel lymph node biopsy during breast cancer surgery for invasive lobular carcinoma and invasive ductal carcinoma

Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases

Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: Case Report and review of the literature

Pancreatic and multiorgan resection with inferior vena cava reconstruction for retroperitoneal leiomyosarcoma

Atypical presentation of angiosarcoma of the scalp in the setting of Human Immunodeficiency Virus (HIV)